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Abstract
The development of dyskinesias following chronic L-DOPA replacement therapy remains a major problem in the long-term
treatment of Parkinson’s disease. This study aimed at evaluating the effect of IRC-082451 (base of BN82451), a novel
multitargeting hybrid molecule, on L-DOPA-induced dyskinesias (LIDs) and hypolocomotor activity in a non-human primate
model of PD. IRC-082451 displays multiple properties: it inhibits neuronal excitotoxicity (sodium channel blocker), oxidative
stress (antioxidant) and neuroinflammation (cyclooxygenase inhibitor) and is endowed with mitochondrial protective
properties. Animals received daily MPTP injections until stably parkinsonian. A daily treatment with increasing doses of L-
DOPA was administered to parkinsonian primates until the appearance of dyskinesias. Then, different treatment regimens
and doses of IRC-082451 were tested and compared to the benchmark molecule amantadine. Primates were regularly
filmed and videos were analyzed with specialized software. A novel approach combining the analysis of dyskinesias and
locomotor activity was used to determine efficacy. This analysis yielded the quantification of the total distance travelled and
the incidence of dyskinesias in 7 different body parts. A dose-dependent efficacy of IRC-082451 against dyskinesias was
observed. The 5 mg/kg dose was best at attenuating the severity of fully established LIDs. Its effect was significantly
different from that of amantadine since it increased spontaneous locomotor activity while reducing LIDs. This dose was
effective both acutely and in a 5-day sub-chronic treatment. Moreover, positron emission tomography scans using
radiolabelled dopamine demonstrated that there was no direct interference between treatment with IRC-082451 and
dopamine metabolism in the brain. Finally, post-mortem analysis indicated that this reduction in dyskinesias was associated
with changes in cFOS, FosB and ARC mRNA expression levels in the putamen. The data demonstrates the antidyskinetic
efficacy of IRC-082451 in a primate model of PD with motor complications and opens the way to the clinical application of
this treatment for the management of LIDs.
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Introduction
Parkinson’s disease (PD) is the most common neurodegenerative
disorder after Alzheimer’s disease affecting the elderly population.
The incidence of this neurological disorder dramatically increases
with age, with more than 1% of the population over 60 being
affected worldwide [1]. Loss of dopaminergic neurons in the
substantia nigra pars compacta (SNc) and consequent dopami-
nergic depletion in the striatum has long been identified as the
underlying cause of PD. The result of this loss is reflected by both
cognitive and motor decline, with cardinal symptoms being
bradykinesia, akinesia, muscular rigidity, postural instability and
tremor. The best symptomatological treatment available for this
progressive neurodegenerative disorder is replacement therapy
with L-DOPA (L-3,4-dihydroxyphenylalanine) [2,3]. Although
this treatment is very efficacious, chronic exposure to the drug
rapidly gives rise to fluctuations in motor response and abnormal
involuntary movements termed dyskinesias that complicate the
management of the disease [4,5].
The two most widely used animal models of PD that display
levodopa-induced dyskinesias (LIDs) under chronic L-DOPA
treatment are the intracerebral injection of 6-OHDA in rats and
the systemic administration of the neurotoxin MPTP (1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine) in primates respectively. The
MPTP monkey model reproduces most of the features seen in PD
patients at the behavioural but also biochemical and histological
levels [6,7,8,9,10,11,12,13]. This model has allowed the investi-
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gation of the neurophysiological and molecular mechanisms
leading to LIDs and the evaluation of potential therapies that
could hamper their development or reduce their severity [14,15].
In this context, we focused our interest on a novel molecule, IRC-
082451 (base of BN82451), that belongs to a family of hybrid
multitargeting compounds capable of inhibiting lipid peroxydation
and of protecting mitochondria against different toxins, reducing
mitochondrial swelling, cytochrome c release and caspase-9
activation [16]. In fact, IRC-082451 exhibits anti-inflammatory
and anti-oxidant properties both in vitro and in vivo and displays
neuroprotective effects in animal models of Huntington’s disease,
cerebral ischemia, PD and amyotrophic lateral sclerosis [16]. The
antidyskinetic effect of IRC-082451 has recently been demon-
strated in 6-OHDA-lesioned dyskinetic rats [17]. The fact that the
mechanism of action of this molecule does not directly involve the
dopaminergic or the serotoninergic pathways [16] makes it an
interesting alternative to existing PD therapies.
In the present pre-clinical evaluation study, we aimed to
evaluate the antidyskinetic properties of IRC-082451 in a primate
model of PD with motor complications. The model was first
validated with amantadine, an NMDA receptor antagonist with
proved efficacy against LIDs [18,19,20,21]. Then, the pharmaco-
logical evaluation of IRC-082451 efficacy against LIDs consisted
in injection of all dyskinetic animals with three different doses (2.5
to 10 mg/kg) and two administration regimes (acute and sub-
chronic), intercalating IRC and vehicle treatments over time.
Video recordings were used to perform a comprehensive
behavioural characterization of the effects of each dose of IRC-
082451 on dyskinetic animals placed under daily L-DOPA
maintenance regime and comparing it to the profile of each same
animal under vehicle treatment. This approach allowed the
precise time-encoded assessment of LIDs and image analysis-based
determination of locomotion after L-DOPA administration. L-
DOPA concentration measurements and positron emission
tomography (PET) scans using 6-[18F] Fluoro-L-Dopa (18F-
DOPA) were performed to exclude any potential direct interaction
of IRC-082451 with the biodistribution/biodisponibility of L-
DOPA. Finally, transcriptomic and histological post mortem analyses
were performed in the putamen of controls, naı¨ve MPTP animals,
and MPTP dyskinetic animals under L-DOPA treatment with
either IRC-082451 or its vehicle PEG400. Results indicate that
IRC-082451 can significantly reduce LIDs in parkinsonian
dyskinetic monkeys without compromising the beneficial effect of
L-DOPA on locomotion, and reverse some of the striatal
molecular anomalies linked to LID.
Materials and Methods
Animals and Housing
All animal studies were conducted according European (EU
Directive 86/609) and French regulations (French Act Rural Code
R 214-87 to 131). The animal facility is authorized by local
veterinarian authorities (authorization nu A 92-032-02) and
complies with Standards for Humane Care and Use of Laboratory
Animals of the Office of Laboratory Animal Welfare (OLAW –
nu#A5826-01). All efforts were made to minimize animal suffering
and animal care was supervised by veterinarians and animal
technicians skilled in the healthcare and housing of non-human
primates. All animals were individually housed under standard
environmental conditions (12-hour light-dark cycle, temperature:
2261uC and humidity: 50%) with free access to food and water.
Experiments were conducted on a total of twelve male cynomolgus
monkeys (Macaca fascicularis, supplied by Noveprim, Mauritius
Island) of a mean age of 561 years and a mean weight of 662 kg.
Experimental Design and Behavioural Analysis
The general workflow of experiments and the different
pharmacological treatment regimens administered are presented
in figure 1. Animals were divided into 3 groups: healthy controls
(CTRL) (n = 3); MPTP-treated parkinsonian controls (MPTP)
(n = 3), MPTP and L-DOPA treated dyskinetic animals (LID)
(n = 6). All LID animals were sequentially treated with vehicle
PEG400 (VEH), the antidyskinetic molecule IRC-082451 (IRC) or
the antidyskinetic molecule of reference amantadine. At euthana-
sia however, LID animals were sacrificed under L-DOPA and
either a 5 day-treatment with IRC (5 mg/kg; n = 3) or vehicle
(n = 3). No animal was sacrificed under the effect of amantadine
treatment.
IRC-082451 from Ipsen Innovation was obtained by removing
HCl from BN82451 and amantadine was purchased from Sigma
Aldrich AB.
All animals were videotaped 5 times before the beginning of the
protocol in order to quantify and characterize normal baseline
locomotor activity with EthovisionH and The ObserverH software
respectively (Noldus, The Netherlands) (Fig. 1A). Briefly, animals
were transported from their home cage to a custom-made video
cage without bars and continuously filmed for 6 hours. Baseline
locomotor activity was quantified as total distance travelled (TDT)
in meters and averaged across all different baseline films using
Ethovision [22,23]. Nine primates received daily intramuscular
injections of 0.2 mg/kg MPTP (1-methyl-4-phenyl-1,2,3,6-tetra-
hydropyridine, Sigma-Aldrich, France) for 7 consecutive days
(Fig. 1A), the remaining 3 being kept as intact controls. Cycles of
MPTP intoxication were repeated if the desired level of
parkinsonism was not achieved in the first 7 days. Average
intoxication time was 2.5 months and cumulative doses of MPTP
received by all primates ranged from 13–35 mg (mean 6 s.e.m.:
23.9764 mg). Animals were filmed for 40 minutes during MPTP
intoxication and stabilisation phases to quantify spontaneous
locomotor activity. Once parkinsonism was satisfactory according
to clinical scores and to a significant reduction in spontaneous
locomotor activity (mean % 6 s.e.m.: 8166.1) that lasted at least
one month, 6 primates received oral doses of L-DOPA (Modopar
125, Levodopa:Benserazide 4:1, Roche) twice a day in order to
induce dyskinesias (Fig. 1A). Primates were filmed for 6 hours on
or off medication and videos were analyzed both with EthovisionH
for locomotor activity quantification and The ObserverH for the
determination of the incidence and type of dyskinesias displayed
by each subject. All LID animals received L-DOPA and a sub-
cutaneous injection of amantadine, the benchmark antidyskinetic
molecule, in order to validate the model used. As shown in
figures 1B and 1C, drugs were tested under two different
administration regimes. In acute treatments, all LID primates
received a sub-cutaneous injection of a given dose of IRC or
amantadine together with L-DOPA and were filmed for 6 hours
(Fig. 1B). After at least 10 days washout, the same LID animals
were administered L-DOPA and injected with vehicle PEG400 as
a control for the acute treatments (Fig. 1B). In sub-chronic
treatments, all LID primates were administered both L-DOPA
and IRC-082451 or amantadine daily for 5 days and filmed on
days 0 and 5 (Fig. 1C). As for acute treatments, a 10 day washout
period were applied before challenging the same LID primates
with the vehicle sub-chronic 5-day injections.
LID Recordings
Quantification of L-DOPA-induced dyskinesias was performed
with The Observer XT specialized software (Noldus, The
Netherlands) [24]. The 6 hour recordings of animals on and off
L-DOPA treatment were used to manually score the total number
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of dyskinesias. The analysis yielded a time-encoded event log of
abnormal behaviours that allowed us to validate the pharmaco-
kinetics of L-DOPA and the incidence of abnormal involuntary
movements in all our LID primates over 6 hours. Following
relevant clinical scales used in PD patients and primates [25,26],
dyskinesias were manually scored in 7 different body parts: upper
limb (right or left); lower limb (right or left); trunk; neck and face.
After 5 months of L-DOPA administration the LID count was
stable, and animals (n = 6) were kept on a maintenance regime
consisting of a daily oral dose of 600 mg of L-DOPA (mean 6
s.e.m.: 566.67655.77), and acute or sub-chronic treatments with
amantadine, IRC or vehicle were alternatively administered. This
same regime of L-DOPA administration was kept during the
wash-out periods in between drugs.
Euthanasia and Tissue Preparation
At euthanasia, LID primates were divided into 2 groups so that
3 were under a sub-chronic treatment with IRC-082451 and 3
under a 5-day treatment with vehicle. Because all dyskinetic
animals had received IRC, amantadine and vehicle treatments
over time, any permanent biochemical changes that could have
been induced by amantadine were equal in all animals at the time
of euthanasia and should not explain the differences observed
between IRC-treated and PEG400-treated primates.
Animals were anesthetized with 10:1 mg/kg ketamine:xylazine
and blood samples were collected on the 5th day of treatment with
IRC-082451 or vehicle and L-DOPA, 2 hours after their
administration. A lethal dose of pentobarbital was delivered before
transcardial perfusion with cold 0.9% NaCl. Brains were extracted
and sliced into 4 mm-thick slices using a coronal cynomolgus brain
matrix (Ted Pella inc., Redding, CA, USA). Biopsy punches were
taken from the anterior (AC+3) and posterior (AC-2) putamen.
Punches were immersed in liquid nitrogen and kept at 280uC
until prepared to be used in either RT-qPCR or HPLC-MS/MS
analysis. The rest of the brain was immediately placed in ice-cold
4% paraformaldehyde for 5 days and sucrose-containing phos-
phate buffer gradients for cryoprotection before immunohisto-
chemistry.
Immunohistochemistry
Brains were sliced into 40 mm-thick sections using a freezing
microtome. Sections were first incubated in 1% H2O2 for 20
minutes and for 30 minutes in phosphate buffer saline (PBS)
containing 4.5% normal goat serum and 0.2% Triton-X100.
Sections were then incubated for 48 h at room temperature in
PBS containing 0.2% triton-X100, 3% normal serum and the
appropriate dilution of the primary antibody, anti-Tyrosine
Hydroxylase (TH) 1:500 (Immunostar, Hudson, USA). After
incubation in the primary anti-serum, sections were processed with
the avidin-biotin peroxidase method. Unbiased stereology using
the optical fractionator method was used to estimate the total
number of TH positive neurons in the substantia nigra using
Mercator software (Explora Nova, La Rochelle, France) as
previously described [27].
Real-time qRT-Polymerase Chain Reaction (PCR)
Putaminal brain samples were processed independently for each
animal (n = 3/group). Total RNAs were extracted using guani-
diumthiocyanate/phenol derived method (Trizol, Invitrogen,
France) followed by digestion with RQ1 DNase (Promega,
France). cDNA synthesis was performed with 2 mg of total RNA
using random hexamers and a reverse transcriptase (RT2 first
Figure 1. Schematic representation of the experimental design and pharmacological treatment protocols. A, general experimental plan
showing phases of behavioural characterization: at baseline, during MPTP intoxication, upon L-DOPA chronic treatment for the development of
dyskinesias, and after antidyskinetic treatment administration. Post-mortem analysis techniques are listed. Detail of the administration of L-DOPA and
treatment with either IRC-082451 (IRC), amantadine (AMANT) or vehicle (VEH) in acute (B) and sub-chronic (C) treatment regimes.
doi:10.1371/journal.pone.0052680.g001
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strand kit ref. C-03, SABiosciences). PCR was carried out with 1%
of the RT product in a 20 ml reaction volume containing Platinum
SYBR Green qPCR SuperMix-UDG (Invitrogen, France), 10 mM
of forward and reverse primers, and 0.5% random-primed cDNA
generated from 200 ng of total RNA. A MastercyclerRealplex
(Eppendorf, France) was programmed for an initial denaturation
step (95uC, 2 min) followed by 40 amplification cycles (95uC for
15 s, 60uC for 1 min). Expression differences were calculated using
the amplification rate of the target as evaluated from serial
dilutions of whole-brain cDNA and corrected for differences in
cDNA input in reference to the expression level of glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) mRNA, assumed to be
constant throughout the brain. Differences between control and
experimental samples were calculated using the DDCt method. All
experiments were carried out on two replicates of each sample.
Primer sequences were designed using Oligo 6.3 software and are
reported on table S1.
HPLC Analysis of IRC-082451 and L-DOPA Levels
Plasma samples and biopsies from cortical brain tissue were
collected from three LID animals at euthanasia after 5 days of sub-
cutaneous treatment with 5 mg/kg IRC-082451 and L-DOPA.
Plasma samples, (50 ml) with added Terfenadin as the internal
standard, were mixed at 4uC with acetonitrile containing 0.1%
formic acid to precipitate the proteins. After centrifugation (2000 g
for 10 min at 4uC), the supernatants were analyzed by HPLC-
MS/MS for the determination of IRC-082451 levels. Samples
taken from the cerebral cortex were weighted and homogenized in
methanol (3 mL/g of tissue) at 4uC using a PolytronH homoge-
nizer (Kinematica) for 60 seconds. The tissue extracts were
centrifuged at 25000 g for 15 min at 4uC. The supernatants
(50 mL) with Terfenadin added as the internal standard were
analyzed by HPLC-MS/MS using a surveyor HPLC (Surveyor
Autosampler and MS Pump, Thermo ElectronH) coupled to a
TSQ Quantum Ultra mass spectrometer (ThermoElectronH)
equipped with an atmospheric pressure electrospray ionization
source. For L-DOPA quantification, samples were prepared by
precipitation of proteins in HClO4 23% perchloric acid in water
(20 min at 4uC) followed by centrifugation at 2000 g for 10 min at
4uC, another cycle of centrifugation at 10000 g for 10 min at 22uC
and filtration. The supernatant was kept and processed for high-
performance liquid chromatography (HPLC) analysis. L-DOPA
concentrations in the supernatant were determined by HPLC with
electrochemical detection. The system consisted of a pump
(Shimadzu model LC-10 AD, Shimadzu Europe, Munich,
Germany), a refrigerated automatic injector (Famos model,
Dionex, France), a reverse-phase Hypersil RP 18 analytical
column (Aquasil 15061 mm, particle size 3 mm; ThermoHypersil,
les Ulis, France) and an electrochemical detector (Decade, Antec,
The Netherlands) equipped with an analytical cell (type VT-03,
Antec). Chromatograms were collected and treated with integra-
tion software (CLAS VP, Shimadzu, France). The mobile phase
consisted of sodium dihydrogen phosphate buffer (NaH2PO4,
50 mM; Merck), octane sulfonic-1 acid sodium salt (1.7 mM;
Merck), disodium ethylenediamine tetra-acetic acid (Na2-EDTA,
200 mM; Merck). The pH was adjusted to 3 with concentrated
phosphoric acid (H3PO4), and 5% acetonitrile (ACN, Sigma) was
added to the final solution. All solvents were filtered through
Millipore filters with 0.22 mm pores (Millipore, France) before use.
The mobile phase was delivered by a pump with a flow rate of
60 ml/min. The working electrode potential was +750 mV, which
represented the best compromise regarding the optimum oxida-
tion potentials of L-DOPA. The running time for each sample
determination was 15 minutes.
Imaging
I. Positron emission tomography scans. PET scan acqui-
sition was performed under propofol anaesthesia (1 mg/kg/hour).
Animals were placed in a PET dedicated stereotactic-like animal
holder with the head resting on a mouth bar, fixed by blunt ear
bars. Temperature was maintained at 37uC using a feed-back
coupled heating blanket, and the respiration rate, pO2, pCO2 and
cardiac rhythm were continuously monitored. 18F-DOPA radio-
tracer (6-[18F] Fluoro-L-Dopa, 200+/230 MBq) was injected
intravenously at the start of data acquisition. Imaging was
performed on a non-human primate dedicated PET scanner with
a 1.5 mm axial resolution 4% sensitivity, the FOCUS 220
(Siemens), using a time coincidence window of 6 ns and energy
discrimination levels between 350 and 650 keV. Data were
acquired during 90 min and list mode data were sorted in 9
frames of 10 min. The attenuation correction factors were
measured with an external 68Ge source before radiotracer
injection. The emission sinograms (i.e. each frame) were normal-
ized, corrected for attenuation and radioactivity decay, and
reconstructed using Fourier rebinning (FORE) and ordered subset
expectation maximization (OSEM) 2D (16 subsets and 4
iterations). Data analyses were performed using the in-house built
and freely available software Brainvisa (http://brainvisa.info/
index_f.html). Left and right putamen were individually segment-
ed on summed 18F-DOPA PET images using intensity scaling,
including pixels with an intensity of 80% of the maximum intensity
value within a defined volume. A spherical region (300 mm3) was
placed in the occipital cortex as a reference region. Time activity
curves representing the mean distribution of the tracer concen-
tration (Bq/cc) within the caudate, putamen and occipital cortex
in function of time were then analysed using the Patlak graphical
method [28]. Equilibrium was considered to occur 30 min after
tracer injection and Ki was obtained as the slope of the Patlak
curve [29].
II. Magnetic resonance imaging. Magnetic resonance
imaging (MRI) was performed on all animals shortly before or
after the PET scan in order to allow precise determination of
regions of interest for PET analysis. Animals were anesthetized
with 10:1 mg/kg ketamine:xylazine and placed in the magnet in a
sphinx position, fixed by mouth and ear bars to a stereotactic
MRI-compatible frame (M2E, France). Once in the magnet,
animals were heated by a hot air flux and their temperature and
respiration parameters monitored remotely.
MRI was performed on a 7 Tesla horizontal system (Varian-
Agilent Technologies, USA) equipped with a gradient coil
reaching 100 mT/m (300 ms rise time) and a circular radiofre-
quency 1H coil (12 cm inner diameter). T2-weighted images were
acquired using a fast spin-echo sequence with the following
parameters: TR = 4750 ms, effective TE = 62 ms, acquisition
time = 16 min, FOV = 1156115 mm and matrix = 2566256 re-
sulting in a 4506450 mm in plane resolution, 40 coronal slices,
slice thickness = 1 mm.
Statistical Analysis
I. Behavioural data. Analysis of variance on raw data
indicated heterogeneous LID baseline from a monkey to another
one (ANOVA: p = 0.0002). Since all LID animals were filmed
under IRC and, after a washout period, under vehicle, each
animal was compared with itself. Accordingly, the LID raw data
was normalised by deriving the percentage of effect on the LID.
No LID being considered as 100% of effect and the LID[PEG400]
for an animal at a treatment period being considered as its 0% of
effect at this period. The general formula is: LID[%effec-
t] = 100*(LID[PEG400]-LID[raw data])/LID[PEG400]. Stu-
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dent’s t test was used to compare the percentage of effect on LIDs
and TDT in relation to 0% (no effect).
II. RT-PCR, histology and PET. All data was analyzed with
Student’s t test or one-way ANOVA followed by Fisher’s PLSD
post hoc test. Data are expressed as mean 6 standard error of the
mean (s.e.m.).
Results
Effect of IRC-082451 in the Brain
I. Brain penetration of IRC-082451. First, plasma and
brain concentrations of IRC-082451 were determined in male
cynomolgus monkeys (Macaca fascicularis) following sub-cutaneous
5-day sub-chronic administration at 5 mg/kg/day. HPLC-MS/
MS analysis of samples collected 2 h after the last injection of
IRC-082451 showed a higher concentration of IRC in the brain
(Cortex: 20.8766.92 mM) than in plasma (1.1660.33 mM), with a
ratio of 18.262.5. This demonstrates that IRC-082451 efficiently
crosses the blood-brain-barrier in non-human primates.
II. Potential interaction between IRC-082451 and L-DOPA
metabolism. In order to rule out the possibility that the
antidyskinetic effect of IRC-082451 was due to a direct
interference of this molecule with the metabolism and entry of
L-DOPA in the brain, the effect of injecting the IRC compound in
the periphery and its bioavailability in the brain were explored
in vivo. Blood samples were taken from all dyskinetic animals 2
hours after administration of L-DOPA and of 5 mg/kg of IRC-
082451 or its vehicle. Analysis of plasma samples using HPLC
separation coupled to electrochemical detection showed that there
was no statistical difference between the two groups (L-DOPA
concentrations = mean 6 s.e.m.: LID-PEG = 276.368.93 ng/
100 ml; LID-IRC = 303.9648.76 ng/100 ml; N.S., p = 0.63), sug-
gesting IRC-08451 did not markedly change L-DOPA metabolism
in the periphery in parkinsonian dyskinetic primates.
In order to further study such potential interference in the brain,
a functional assessment by PET was performed in parallel in a
separate group of primates. Three healthy animals received a sub-
cutaneous injection of either 5 mg/kg IRC-082451 or its vehicle
PEG400 2 hours before being anesthetized for the imaging session.
18F-DOPA radiolabelled tracer was injected intravenously at IRC
Cmax and the acquisition lasted 90 minutes. PET images were co-
registered with anatomical MRI images in order to determine
regions of interest in the striatum and a region of reference in the
occipital cortex. Patlak analysis revealed that the influx constant
(Ki) of the radioactive tracer in striatal dopaminergic terminals was
not different in animals that had been injected with IRC-082451
and those injected with vehicle and that accumulation of 18F-
DOPA over time was comparable as shown by the images
reported in figure 2A. In fact, the Ki coefficients (,0.016 min21
in normal intact NHP) calculated from the regions of interest
drawn in the caudate and putamen of the right and left
hemispheres were not significantly different amongst animals
regardless of the treatment received (Ki 6 s.e.m.:
PEG400 = 0.01560.001; IRC-082451 = 0.01760.001) (Fig. 2B).
This indicates IRC-082451 acts on dyskinesias through a
mechanism different from the direct interference with L-DOPA
brain uptake and/or metabolism.
Effect of Amantadine on Dyskinesias and Locomotor
Behaviour
Although the primate model chosen for this study has been
extensively used to evaluate therapeutic strategies for PD, we
wanted to confirm that our dyskinetic primates responded to
treatment with amantadine, the NMDA glutamate receptor
antagonist most widely used in the clinic to reduce LIDs [18].
Three doses of amantadine were tested acutely based on published
results in non-human primates [30,31,32,33]. Locomotor activity
was quantified using Ethovision software and the incidence of
abnormal movements was rated using The Observer software. All
LID animals were given L-DOPA and an acute injection of either
vehicle or a given dose of amantadine (2.5, 5 and 10 mg/kg)
respecting a 10-day washout period between treatments. Results
indicated that amantadine significantly reduced dyskinesia score
by approximately 30% only at the 10 mg/kg dose (p,0.05)
(Fig. 3A). No significant effect was observed on locomotor activity
for all amantadine doses as compared to vehicle (Fig. 3B). Based
on these results, the 10 mg/kg dose was tested on a sub-chronic 5-
day regime. Results also showed a significant effect of 39%
(p,0.001) on dyskinesias by day 5 (Fig. 3C) and no effect on
locomotor activity (Fig. 3D). Overall, this suggests that LID
primates were responsive to a validated antidyskinetic agent and
were suitable for investigating the effect of the novel compound
IRC-082451.
Effect of IRC Treatment on Dyskinesias and Locomotor
Behaviour
Figure 4A summarizes the effect observed on dyskinesias for all
acute doses of IRC-082451 tested in our LID primates. The
2.5 mg/kg dose had no beneficial effect on the number or type of
dyskinesias following L-DOPA treatment. In contrast, a significant
43% reduction of the total number of dyskinesias (p,0.01) was
observed at the 5 mg/kg dose suggesting an antidyskinetic effect of
the compound. Animals also responded acutely to the 10 mg/kg
dose showing a 25% reduction in dyskinesias (p,0.05) (Fig. 4A).
Figure 4B shows there was no significant effect of IRC-082451 on
spontaneous locomotor activity across all acute treatments tested.
An example of the time-encoded analysis of dyskinesias in a single
animal using The Observer software is reported in figures 4C
(PEG) and D (IRC). Statistical analysis showed there was no
significant correlation between the antidyskinetic effect of IRC-
082451 and a specific body part scored or a specific time after
administration over the 6 hours of film (data not shown).
Although no significant difference was found between the
antidyskinetic effect of IRC-082451 at 5 and 10 mg/kg when
injected acutely (p,0.5), the 5 mg/kg dose showed a tendency to
further reduce the incidence of dyskinesias. Interestingly, The
Observer analysis highlighted that the incidence of dyskinesias
begun to lower 2 hours after the administration of 5 mg/kg of
IRC-082451. In order to test whether this ‘‘delayed’’ effect of IRC
was due to its reaching Cmax at a slower rate than L-DOPA, a
different acute treatment was implemented for this dose. All
dyskinetic primates received 5 mg/kg of IRC or VEH at time 0
and L-DOPA 2 hours later. Animals were then filmed for 6 hours.
Results reported in figure 5A show that a significant 43%
reduction in dyskinesias (p,0.01) was then achieved acutely
together with a significant 42% increase in locomotor activity
(p,0.04; fig. 5B). The fact that IRC and L-DOPA did not reach
peak effect at the same time could be due to the pharmacokinetics
of each compound and to the different administration routes used
for IRC (s.c.) and L-DOPA (p.o.). Based on these results, the
5 mg/kg dose was chosen to perform a 5-day sub-chronic
treatment in all LID animals. As shown in figure 6A, sub-chronic
treatment with the 5 mg/kg dose of IRC-082451 had a significant
antidyskinetic effect (p,0.001) and, more importantly, locomotor
activity was significantly increased by 35% (p,0.01) on day 5 of
treatment on all LID primates (Fig. 6B).
We were then curious to know whether the IRC molecule
conferred protection 24 hours after the last administered dose.
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After a 10-day washout, we proceeded to a 4 day treatment with
L-DOPA and 5 mg/kg IRC-082451 and filmed all LID animals
on the 1st and 5th day (Fig. 7A). Interestingly, the treatment
continued to be effective on dyskinesias (p,0.005) (Fig. 7B)
although no increase in locomotor activity was observed (Fig. 7C).
Finally, the administration of IRC-082451 or its vehicle
PEG400 in the absence of L-DOPA had no effect on spontaneous
locomotor activity (data not shown).
Post-mortem Characterization of the Effect of IRC-082451
Treatment on Dyskinesia
I. IRC-082451 effects on gene expression. Quantitative
RT-PCR assays were performed for several different genes
previously identified in the literature as key players in pathways
involved in dyskinesias in animal models of PD. Primers were
designed for the transcriptional regulators FosB and cFOS, the
glutamate ionotropic receptor (GRIN2B/NR2B), the homer
homologue 1 (Homer), the proenkephalin (PENK1), the pre-
prodynorphin (PDYN), the glutamic acid decarboxylase 1
(GAD67), the serotonin receptor type 1A (5HTR1A), the
metabotropic glutamate receptor type 5 (mGluR5) and the
activity-regulated cytoskeleton-associated protein (ARC) (see
Table S1).
ANOVA indicated no statistically significant differences be-
tween groups for seven out of the ten genes tested (see figure S1).
This is most likely due to the limited number of animals included
in each group (n = 3) and the limited amount of brain tissue that
can be recovered for PCR experiments while preserving some
tissue for histological analysis. However, in agreement with most of
the literature dealing with dyskinesias, significant changes were
Figure 2. 18F-DOPA PET studies in IRC-082451-treated and vehicle-injected healthy animals. Representative results of one subject
treated with both molecules on different days taking the occipital cortex as a reference region. Coronal PET image (upper left panel) and
corresponding anatomical T2-weighted MRI images (upper right panel) showing the normal accumulation of the radiotracer in the caudate and
putamen (A).Time activity curves (lower panel) demonstrate there is no significant difference between treatments in either the caudate-putamen
complex (Put) or the occipital cortex (Ctx) curves. Data are expressed as mean 6 s.e.m.
doi:10.1371/journal.pone.0052680.g002
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observed in FosB and cFOS mRNA levels in the putamen of
parkinsonian dyskinetic animals that were corrected after sub-
chronic treatment with IRC-082451. In fact, as expected from the
animal model, FosB mRNA expression levels were higher in the
putamen of LID animals under chronic L-DOPA and treated with
vehicle when compared to healthy controls (p,0.03). IRC
treatment fully reversed such increase (p,0.02 vs VEH)
(Fig. 8A). cFOS levels were similarly higher in vehicle-treated
dyskinetic animals than in MPTP parkinsonian animals and
healthy controls (p,0.001), an effect fully reversed by IRC-082451
sub-chronic treatment (p,0.01 vs VEH) (Fig. 8B).
Interestingly, changes in a novel gene were also found in this
model. ARC mRNA levels were significantly increased in the
putamen of dyskinetic vehicle-injected primates compared to
healthy controls (p,0.001) while a significant reduction of ARC
was observed in dyskinetic IRC-082451-treated animals (p,0.005
vs VEH) (Fig. 8C). A MANOVA analysis on the expression levels
of all the above mentioned genes and the responsiveness to the
IRC-082451 treatment in dyskinetic animals was carried out.
Dyskinesia counts of the same animals on L-DOPA and either
vehicle or IRC-082451 were used to calculate a percentage of
response to the antidyskinetic treatment. Supporting the RT-
qPCR data, ARC significantly correlated with responsiveness to
the IRC-082451 treatment (p,0.05).
II. Characterization of the dopaminergic lesion. Figure 9
shows representative brain sections of monkeys in each treatment
group stained for TH in order to assess the level of dopaminergic
deafferentation in the striatum (Fig. 9A, C, E, G) and cell loss in
the substantia nigra pars compacta (Fig. 9B, D, F, H). Healthy
controls presented a strong dark signal in the striatum and SNc
that was severely reduced (,90%) in animals that underwent
MPTP intoxication, suggesting a similar level of dopamine
depletion across groups. Stereological counts in the SN confirmed
there were no significant differences in the number of TH-positive
neurons between MPTP parkinsonian controls, LID-vehicle-
treated and LID-IRC-treated animals (Fig. 9I), whereas all of
these groups were significantly (p,0.001) different from healthy
controls.
Discussion
The present study demonstrates the efficacy of the novel
multitargeting hybrid molecule, IRC-082451, in reducing the
incidence of L-DOPA-induced dyskinesias in the MPTP primate
model of PD. The antidyskinetic effect of this compound was
significant acutely, after a sub-chronic 5-day treatment period and
even 24 hours after the last administered dose. The effect of IRC
was compared to that of amantadine at three incremental doses.
Figure 3. Effect of amantadine treatment on motor behaviour. Three different doses of amantadine were acutely injected together with L-
DOPA and a significant antidyskinetic effect was observed at the 10 mg/kg dose (A). Ethovision analysis of the total distance travelled (TDT) shows
there is no effect on locomotor activity of either dose of amantadine tested (B). Sub-chronic 5-day treatment with 10 mg/kg amantadine further
confirms the antidyskinetic efficacy of the compound (C) and the lack of significant effect on locomotor activity compared to vehicle treatment (D).
Data are presented as mean 6 s.e.m. Unpaired Student t test (*, p,0.05).
doi:10.1371/journal.pone.0052680.g003
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Both compounds were clearly ineffective at the 2.5 mg/kg dose,
IRC and not amantadine was efficacious at the 5 mg/kg dose and
both compounds showed an antidyskinetic effect at the 10 mg/kg
dose. The antidyskinetic effects of 5 and 10 mg/kg doses of IRC-
082351 were not significantly different suggesting that the
maximal beneficial effect of this compound was reached at
5 mg/kg in our LID model. The behavioural analysis carried out
consisted of a manual continuous 6 h neurological scoring of LIDs
following L-DOPA ingestion and a concomitant automated
quantification of the spontaneous locomotor activity displayed by
primates during the same 6 hours. This made it possible to observe
that the antidyskinetic effect of IRC-082451 was associated with a
significant increase of the beneficial effect of L-DOPA on the total
distance travelled after a 5-day treatment with IRC-082451.
Detailed analysis of leg, arm, trunk, neck and oro-lingual
dyskinesia suggested there was no exclusive effect of IRC-
082451 on dyskinesia affecting a particular body part nor a
particular type of dyskinesia. These results are consistent with and
further support those obtained in dyskinetic 6-OHDA rats where
the antidyskinetic properties of acute and sub-chronic treatments
of IRC-082451 have been recently reported [17]. From a clinical
standpoint, our behavioural analysis suggests that IRC-082451
could at least partially alleviate LIDs in PD patients under chronic
L-DOPA therapy and may also allow the reduction of L-DOPA
doses without compromising its beneficial effect on akinesia.
Several compounds have been tested for their potential effects
against LIDs in the MPTP model of PD in non-human
primates. They cover a variety of therapeutic targets such as
glutamatergic receptors (amantadine) [30,32], mu-opioid recep-
tors (ADL5510) [34], nicotinic receptors [35] and the serotonin
transporter blocker (3,4-methylenedioxymethamphetamine) [36].
The heterogeneity in the choice of animal model, the
Figure 4. Time-encoded video-based analysis of motor behaviour after acute treatment with escalating doses of IRC-082451.
Quantification of L-DOPA-induced dyskinesias at 2.5, 5 and 10 mg/kg IRC-082451 compared to vehicle (0)(A). Total distance travelled (TDT) in meters
as measured by Ethovision at different IRC doses compared to vehicle (B). Visualization of dyskinesia count output from The Observer software under
vehicle (C) and after an acute 5 mg/kg IRC treatment (D). Horizontal lines represent a part of the body displaying dyskinesias whereas vertical
coloured lines represent an individual dyskinetic event over time. Data are expressed as mean 6 s.e.m. Unpaired Student t test (*, p,0.05; **,
p,0.01).
doi:10.1371/journal.pone.0052680.g004
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administration route of the compounds and the functional
assessment used in these studies makes it difficult to reliably
compare the efficacy of IRC-082451 to that of such potential
antidyskinetic agents. However, treatment with the reference
molecule amantadine confirmed that our LID primates were
responsive to an antidyskinetic agent as expected. Interestingly,
the therapeutic effect of IRC-082451 against LIDs was
accompanied by an increased beneficial effect of L-DOPA on
locomotor activity. The effect of IRC-082451 on L-DOPA-
induced reduction of akinesia is not due to a direct effect on
locomotion since the IRC-treatment alone did not change the
locomotor activity of MPTP primates in the absence L-DOPA.
Moreover, an interesting property of IRC-082451 resides in its
pharmacodynamic characteristics. We showed that following a
4-day treatment, its efficacy lasted for a further 24 h, allowing
significant reduction of LIDs on the 5th day. To the best of our
knowledge, such delayed effect has never been reported for
other compounds, suggesting that in a clinical perspective, IRC-
082451 treatment might provide relatively stable effects even in
cases of poor patient compliance.
A reduction in the incidence of dyskinesias might simply be due
to an acceleration of L-DOPA elimination or an alteration of its
cerebral metabolism, leading to reduced dopamine synthesis.
However, this is unlikely for IRC-082451, since the compound
decreased the number of LIDs while increasing locomotion,
indicating that the L-DOPA treatment remained centrally
efficacious. In addition, an in vivo PET imaging study demonstrat-
ed that there was no significant interaction between IRC-082451
and 18F-DOPA suggesting that the effect on locomotor activity
and dyskinesia is unlikely related to the compound’s direct
interaction with L-DOPA or dopamine cerebral metabolism.
These findings were further confirmed by the in vivo HPLC dosage
that showed that L-DOPA plasma levels were similar in animals
treated with IRC-082451 or its vehicle.
As a multi-targeting molecule, the IRC compound possesses
several properties that cooperate to interfere with several signalling
paths involved in LID. IRC has been shown to act as an anti-
oxidant and a sodium channel blocker, thus protecting neurons
from two plausible mechanisms underlying the pathophysiology of
LIDs: excitotoxicity and free radical-induced damage resulting in
dysfunctional mitochondria [16]. In fact IRC-082451 can protect
mitochondria from MPP+ and Ca2+ induced-permeability transi-
tion and cytochrome c release, all events linked to the triggering of
apoptosis. Thanks to its mitochondrial protective properties, this
treatment could compensate for the chronic oxidative stress
induced by L-DOPA during its metabolism and the reduced
Figure 5. Effect of a delayed acute treatment with IRC-082451
on locomotor activity. A single dose of 5 mg/kg of IRC was given 2
hours before administration of L-DOPA and the total number of
dyskinesias and distance travelled on the same day are presented. A
significant reduction in LID count was observed (A) together with an
increase in spontaneous distance travelled (B) compared to the same
animals under vehicle treatment. Data are presented as mean 6 s.e.m.
Unpaired Student t test (**, p,0.01).
doi:10.1371/journal.pone.0052680.g005
Figure 6. Effect of a sub-chronic treatment with IRC-082451 on
locomotor activity. The 5-day sub-chronic treatment with 5 mg/kg
IRC was given concomitantly with L-DOPA and the total number of
dyskinesias and distance travelled on day 5 are presented. A significant
reduction in LID count was observed (A) together with an increase in
spontaneous TDT (B) compared to the same animals under vehicle
treatment. Data are presented as mean6 s.e.m. Unpaired Student t test
(**, p,0.01).
doi:10.1371/journal.pone.0052680.g006
Figure 7. Effect of a 4-day treatment with IRC-082451 (5 mg/
kg/day). The sub-chronic treatment was given concomitantly with L-
DOPA for 4 days and animals were filmed on the 5th day (A). Total
number of dyskinesias (B) and total distance travelled (C) over 6 h of
film are presented and a significant reduction in LID counts is observed.
Data are expressed as mean 6 s.e.m. Unpaired Student t test (**,
p,0.01).
doi:10.1371/journal.pone.0052680.g007
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mitochondrial energy output resulting from dyskinesia [37].
Moreover, indirect regulation of glutamate release, a neurotrans-
mitter majorly involved in dyskinesias, is also mediated by the IRC
compound in vitro and in vivo thanks to its sodium channel blocker
properties. Finally, unlike many proposed antidyskinetic treat-
ments, the mechanism of action of this compound does not directly
target dopaminergic, serotoninergic or glutamatergic receptors
[16], thus offering a new alternative therapeutic strategy against
dyskinesias.
Although the underlying mechanisms of action of IRC-082451
against LIDs are yet to be fully deciphered, post mortem analyses
of the striatum of dyskinetic animals suggest that sub-chronic IRC
treatment can reverse some of the molecular anomalies associated
with LID. We observed a reduction in the upregulation of FosB
and cFos mRNA in dyskinetic animals that were responsive to the
treatment with this molecule as compared to vehicle-treated
dyskinetic controls. We found that the activity-regulated cytoskel-
eton-associated (Arc) gene was strongly upregulated upon dopa-
minergic depletion and dyskinesias and that its expression levels
were normalized after IRC-082451 treatment. Experiments in
dyskinetic rats treated with chronic L-DOPA have shown
upregulation of ARC mRNA and protein in dynorphin-containing
striatonigral neurons that correlated to the severity of abnormal
movements [37,38]. In line with our findings, the effect of IRC-
082451 on ARC mRNA expression in 6-OHDA rats with LIDs
has also been recently published [17]. Moreover, in our study,
FosB, a known marker of LIDs, was increased in dyskinetic
vehicle-treated animals and downregulated in dyskinetic IRC-
treated primates. A significant correlation was found between
ARC and FosB mRNA levels. ARC appears as a key molecular
player in the reduction of dyskinesia in both rodent and primate
models of PD. The induction of ARC mRNA and synaptic
localization of the protein are both regulated by NMDA receptors
as shown by experiments on long-term potentiation, learning and
memory in rodents (reviewed in [39,40,41]). Several groups have
described the role of synaptic remodelling in LIDs, comparing
them to an aberrant form of motor ‘‘patterning’’ or ‘‘learning’’
[42,43,38], alterations of the glutamatergic synapse being central
in the physiopathology of LIDs [44]. ARC is associated to NMDA
glutamatergic receptors as well as regulating AMPA receptor
trafficking [41,38,45]. It forms a protein complex with PSD95 and
CAMKII and has been localized to the PSD in dendritic spines
(see [39]). ARC could have a dual function acting indirectly on
glutamate release as well as enhancing synaptic plasticity. Further
studies are necessary to elucidate the role of this protein in LIDs
and to determine the precise mechanism through which the IRC
molecule exerts its antidyskinetic effect in preclinical models of
PD.
In summary, thanks to the unique combination of motor activity
and involuntary movement recording analysis, our results show
that IRC-082451 treatment enhances the benefit of L-DOPA
pharmacotherapy by reducing LIDs and increasing spontaneous
locomotion. Plasma dosages and PET imaging experiments rule
out the possibility that the reduction in dyskinesias is due to a
reduced bioavailability of L-DOPA in the primate brain. The
behavioural effect IRC-082451 is related to the attenuation of the
aberrant molecular changes likely related to abnormal glutamate
transmission in the striatum, including increases in ARC, cFos and
FosB expression. This supports the hypothesis that IRC-082451
has an effect on synaptic remodelling that in turn regulates the
long-term motor maladaptive alterations caused by LIDs, thus
linking changes in synaptic connectivity with behavioural
outcome.
Figure 8. RT-qPCR analysis of putaminal brain samples in
healthy controls (CTRL), parkinsonian untreated (MPTP),
dyskinetic vehicle-treated (VEH) and dyskinetic IRC-082451-
treated non-human primates. Significant differences in mRNA levels
were detected for FosB (A), cFOS (B) and ARC (C) when comparing
dyskinetic IRC-treated and dyskinetic vehicle-treated animals. Data are
expressed as mean 6 s.e.m. One way ANOVA followed by a post hoc
Fisher’s PLSD test (*, p,0.05; **, p,0.01).
doi:10.1371/journal.pone.0052680.g008
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Supporting Information
Figure S1 RT-qPCR analysis of putaminal brain sam-
ples in healthy controls (CTRL), parkinsonian untreated
(MPTP), dyskinetic vehicle-treated (VEH) and dyskinetic
IRC- 082451-treated non-human primates for seven
different genes implicated in dyskinesias. F and p values
are reported for each of the genes tested: the glutamate ionotropic
receptor (GRIN2B/NR2B), the homer homologue 1 (Homer), the
proenkephalin (PENK1), the preprodynorphin (PDYN), the
glutamic acid decarboxylase 1 (GAD67), the serotonin receptor
type 1A (5HTR1A), the metabotropic glutamate receptor type 5
(mGluR5) and the activity regulated cytoskeleton-associated
protein (ARC). Data are expressed as mean 6 s.e.m. One way
ANOVA showed no statistically significant differences between
groups for these markers. The F and p values of the ANOVA are
indicated on the top left corner of each panel.
(TIF)
Table S1 Sequences of all primers used for qPCR
analysis. Sequences for forward (F) and reverse (R) primers are
reported for all genes explored including PPIA, GAPDH, PENK1,
GAD67, ARC, PDYN, cFos, FosB, GRIN2B, Homer, HTR1A,
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